NAD+ Therapy: Hype, Evidence, and the Compounding Pharmacy Model

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

NAD+ therapy has become one of the most widely marketed interventions in the longevity wellness category. IV drip clinics offer NAD+ infusions for fatigue, cognitive performance, recovery, and anti-aging. Supplement companies sell NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) with claims about cellular energy and longevity. Compounding pharmacies prepare injectable and intranasal NAD+ formulations. The market across all formats has grown substantially over the past five years.

The published research, in contrast, has grown more cautiously. The preclinical literature on NAD+ biology in animal models of aging is substantial and continues to expand. The human clinical trial literature is smaller, more recent, and more measured in its conclusions. The gap between the marketing claims and the published human evidence is the principal feature of the NAD+ category that a careful reader should understand.

This article describes what NAD+ is biologically, what the research base actually supports in humans, and where the boundary sits between documented findings and commercial claims.

What NAD+ is

Nicotinamide adenine dinucleotide is a coenzyme present in every cell of the body. It exists in two interconvertible forms, NAD+ (the oxidized form) and NADH (the reduced form). NAD+ functions as an electron acceptor in central metabolic pathways including glycolysis, the citric acid cycle, and oxidative phosphorylation. Without NAD+, cellular energy production cannot proceed.1

NAD+ also serves as a substrate for several non-metabolic enzyme families. The sirtuins, a family of NAD+-dependent deacetylases, use NAD+ as a co-substrate in their catalytic activity. The poly-ADP-ribose polymerases (PARPs), involved in DNA damage responses, also consume NAD+. The CD38 enzyme, which produces calcium-mobilizing second messengers, is another major NAD+-consuming activity. These non-metabolic functions are the basis of the broader biological interest in NAD+ beyond its established role in energy metabolism.2

NAD+ levels in tissues are dynamic. Synthesis occurs through multiple pathways, including de novo synthesis from tryptophan, the salvage pathway that recycles nicotinamide, and the preiss-handler pathway that uses dietary niacin (vitamin B3). Consumption occurs through the metabolic and non-metabolic pathways above. The net tissue level reflects the balance between synthesis and consumption.

The aging hypothesis

The mainstream scientific interest in NAD+ for aging stems from a series of findings, beginning in the mid-2000s, that NAD+ levels decline with age in several tissues in animal models. The declines have been documented in skeletal muscle, liver, and brain in rodents, and to a lesser extent in human tissue samples obtained at autopsy or biopsy. The decline appears to be driven primarily by increased NAD+ consumption (particularly by CD38) and possibly by changes in salvage pathway activity, rather than by absolute decreases in synthesis.3

The aging hypothesis holds, in summary, that restoring NAD+ levels in older organisms may improve some of the physiological functions that depend on NAD+. The hypothesis has been examined extensively in animal models, where NAD+ precursor supplementation has produced measurable improvements in mitochondrial function, exercise capacity, glucose tolerance, and other markers in aged rodents. The animal data, while substantial, is not the same as human clinical data.4

The human trial evidence

Human clinical trials of NAD+ precursor supplementation, predominantly with nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), began in earnest around 2016 and have continued through the present. The trials have examined effects on biomarkers (NAD+ levels in blood and tissue, metabolic parameters), physical performance, and a range of clinical endpoints in different populations.

The findings to date can be summarized as follows. NR and NMN supplementation reliably increase blood and tissue NAD+ levels in humans, demonstrating that orally administered precursors are bioavailable and reach the relevant cellular pools.5 The clinical endpoints downstream of NAD+ restoration have been more variable. Some trials have reported modest improvements in glucose tolerance, blood pressure, or specific functional measures in particular populations. Other trials have reported no significant effects on their primary endpoints. The trials have generally been small, ranging from a few dozen to a few hundred subjects, and short, ranging from a few weeks to several months. None have been powered to detect effects on long-term outcomes like all-cause mortality, cardiovascular events, or cognitive decline rates.6

The most informed reading of the current state of human evidence is that NAD+ precursor supplementation safely raises NAD+ levels in healthy and older adults. Whether this NAD+ elevation produces clinically meaningful health outcomes, and which outcomes if any, has not been resolved. The marketing claims that have driven the consumer NAD+ market substantially outrun the published clinical evidence.

IV NAD+ versus oral precursors

A separate question from the NAD+ precursor literature concerns the direct intravenous administration of NAD+ itself, the IV infusion model that anchors the wellness clinic market. The mechanism of IV NAD+ is conceptually different from oral precursor supplementation. Oral precursors are absorbed, distributed, and converted to NAD+ inside cells through the normal salvage pathway. IV NAD+ delivers the coenzyme directly to the bloodstream, where it is broken down by extracellular enzymes (particularly CD38) and the breakdown products are taken up by cells, then resynthesized into NAD+ inside the cell.

The published evidence on IV NAD+ infusion in humans is substantially thinner than the evidence on oral precursors. A small number of clinical trials have examined IV NAD+ in specific populations (alcohol use disorder, post-acute COVID-19 recovery, Parkinson disease). The studies have generally been small, often single-arm, and have not demonstrated effects on validated clinical endpoints with the statistical rigor that would support broad therapeutic claims.7

The bioavailability question (how much of an IV NAD+ dose actually reaches the intracellular NAD+ pool of relevant tissues) is also not fully resolved. The breakdown of NAD+ in the bloodstream by extracellular enzymes is rapid. The downstream cellular uptake of the breakdown products has been studied, but the net effect on tissue NAD+ pools from a single IV infusion has not been well-characterized in humans. The wellness clinic claims about IV NAD+ effects on cognition, energy, and recovery are not supported by clinical trial evidence at the level the FDA would require for any approved indication.

The compounding pharmacy and Rx model

NAD+ is available through 503A and 503B compounding pharmacies in several formats: IV infusion, subcutaneous injection, and intranasal spray. The compounding pathway provides a regulated alternative to the unregulated IV drip clinic market and the consumer supplement market. A 503A pharmacy preparing NAD+ for a physician's patient is operating under the same legal framework as for any other compounded preparation: physician prescription, pharmacy preparation under USP standards, and chain-of-custody documentation.

The regulatory framing matters because the wellness clinic IV NAD+ market has operated, in many cases, outside the standards that apply to prescription compounded preparations. The FDA has not taken broad enforcement action against IV drip clinics on NAD+ specifically, though the agency has periodically issued guidance on the legal limits of "wellness" IV preparations and on the requirements for prescription-only injectable products.8

What an honest summary looks like

NAD+ is real biology. The age-related decline of NAD+ levels in certain tissues is documented. The animal literature on NAD+ precursor supplementation in aged rodents is substantial and largely consistent in showing physiological improvements. None of this is in doubt.

The human clinical evidence on NAD+ supplementation, by oral precursor or by direct infusion, is more limited than the marketing suggests. Precursors safely raise NAD+ levels. Whether that elevation produces meaningful clinical benefits remains under active investigation. IV NAD+ is an even less mature evidence category, with thin published trial data on humans for any specific indication. The wellness market has run ahead of the evidence in both categories.

This is not a reason to dismiss NAD+ biology as a legitimate research area. It is the longevity research area with the most active development of clinical-trial-grade evidence. The next five years will likely produce substantially more human data, particularly on long-term outcomes that the current trial set has not addressed. A reader trying to make sense of the category in 2026 is reading it in the middle of a transition from preclinical-dominant to clinical-trial-dominant evidence.

What a careful reader should retain is the distinction between three things that the current market often conflates: NAD+ biology (well-established), NAD+ precursor supplementation in animals (well-studied, generally positive), and NAD+ precursor or IV administration in humans for specific clinical outcomes (still being characterized). The first two support the scientific interest in the category. The third is where the marketing claims most often outrun what has actually been demonstrated.

Footnotes

1. Verdin E. "NAD+ in aging, metabolism, and neurodegeneration." Science. 2015;350(6265):1208-1213. https://pubmed.ncbi.nlm.nih.gov/26785480/
   
2. Cantó C, Menzies KJ, Auwerx J. "NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus." Cell Metab. 2015;22(1):31-53. https://pubmed.ncbi.nlm.nih.gov/26118927/
   
3. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. "CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism." Cell Metab. 2016;23(6):1127-1139. https://pubmed.ncbi.nlm.nih.gov/27304511/
   
4. Yoshino J, Baur JA, Imai S. "NAD+ intermediates: the biology and therapeutic potential of NMN and NR." Cell Metab. 2018;27(3):513-528. https://pubmed.ncbi.nlm.nih.gov/29249689/
   
5. Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nat Commun. 2018;9(1):1286. https://pubmed.ncbi.nlm.nih.gov/29599478/
   
6. Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229. Representative example of a human NMN trial. https://pubmed.ncbi.nlm.nih.gov/33888596/
   
7. Examine.com summary of NAD+ supplementation literature. https://examine.com/supplements/nicotinamide-riboside/ and related entries.
8. FDA, "Compounding and the FDA: Questions and Answers." https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
   
9. MIT Technology Review, "Peptides are everywhere. Here is what you need to know," February 2026. https://www.technologyreview.com/2026/02/23/1133522/peptides-are-everywhere-heres-what-you-need-to-know/
   
10. Conze D, Brenner C, Kruger CL. "Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults." Sci Rep. 2019;9(1):9772. https://pubmed.ncbi.nlm.nih.gov/31278280/